Easy, cheap exposure to Russian stocks

(Full access for Lifetime Members only)

 Exclusive report for Lifetime Members only

 Exclusive report for Lifetime Members only

Easy, cheap exposure to Russian stocks

12 April 2022

The war in Ukraine might soon enter a decisive phase and the West reportedly plans to up sanctions against Russia yet further, so we may see another sell-off of anything Russian.

For private investors who don't have the kind of market access that institutional investors get through global firms like Goldman Sachs, this is probably the single-best way to get diversified exposure to Russian blue-chip equities.

You might be wondering…

  • What kind of investment is it?
  • Why is it available?
  • What is the potential upside?

What I can say is that this is an opportunity with limited availability. The market cap of the company in question simply isn't large enough, which is why this opportunity is only shared with my much smaller group of Undervalued-Shares.com Lifetime Members.

How to buy a slice of distressed Russian assets has genuinely been the most often asked question among my readers.

This report delivers an in-depth, practicable answer to those of you who were scratching their head about this.

Not a Lifetime Member yet? Sign up for a Membership - just USD 999/one-off.
Already a Lifetime Member? Log into your account to download the report.

l  Report updates

Not a Member yet? Sign up for a Membership.
Already a Member? Log into your account to download the report updates.

14 December 2022

Report Update (PDF - 0.2MB)

18 July 2022

Report Update (PDF - 0.1MB)

17 May 2022

Report Update (PDF - 0.4MB)

Most recent

Latest reports (for Members only)

2-2.5x from an investment holding liquidation

2-2.5x from an investment holding liquidation

This AIM-listed small-cap will likely return all its capital to shareholders. Underresearched by investors, it's an opportunity that shouldn't even exist – but it does.

Ukraine reconstruction: one stock to benefit

Ukraine reconstruction: one stock to benefit

If or when the war in Ukraine ends, this stock will likely become the focus of investor money pushing into the country.

Actinium-225, aka "the world's rarest drug"

Actinium-225, aka "the world's rarest drug"

This little-known Western European company could become the global market leader for supplying the uber-rare "Ac-225", a potent weapon to treat cancer.